Skip to content

TG Therapeutics

US · TGTX #1638 by market cap Listed 1970
63.34 -1.54 -2.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 64.30 -0.89%
After-hours 63.21 -0.21%
Overnight 66.26 +2.13%
66.1236.6463.342026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TGTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +66.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 18.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 94.5x Better than 4%
Forward P/E 24.2x Better than 27%
Price / Sales 10.9x Better than 10%
P/E vs own 5-yr range 88th pctl Better than 18%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 83.7% Better than 93%
Operating margin 20.0% Better than 76%
Net margin 72.6% Better than 99%
Return on equity 102.8% Better than 98%
Return on invested capital 67.8% Better than 99%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 16.7% Better than 95%
6-month return 63.0% Better than 97%
12-month return (ex latest month) 69.5% Better than 90%
Distance below 52-week high 6.9% Better than 91%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.1x Better than 82%
Debt to assets 23.9% Better than 50%
Interest coverage 5.0x Better than 56%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 20.6% Better than 34%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.81%
1M +16.16%
3M +25.28%
6M +59.31%
YTD +112.48%
1Y +108.01%
3Y +394.07%
5Y +159.48%

Key statistics

Price & volume

Prev close
64.88
Open
64.10
Day range
63.12 - 65.64
Avg price
64.03
Volume
2.09M
Turnover
133.78M
Amplitude
3.89%
52-week range
26.76 - 68.03

Valuation

P/E
22.87
P/E (TTM)
94.54
P/B
16.73
EPS
2.77
Net profit
418.68M
Net assets
572.09M

Share structure

Market cap
9.57B
Float cap
9.16B
Shares out
151.15M
Float shares
144.54M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 89% of range
26.76 68.03

6.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.40M net over the window

Short interest

Shares short
28.77M
As of
2026-10-30

Frequently asked questions

What is the current stock price of TG Therapeutics (TGTX)?

TG Therapeutics last traded at 63.34. This page shows a periodic quote snapshot. Check the displayed quote time.

What is TG Therapeutics's market cap?

About 9.57B.

What is the P/E ratio of TG Therapeutics?

The trailing twelve-month P/E is 94.54, above its own 5-year average of 7.41 — toward the top of its historical range (87.56% percentile). See the Valuation tab for the full history.

Does TG Therapeutics pay a dividend?

TG Therapeutics does not currently pay a regular dividend.

Is TG Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 76.40, which implies 20.6% upside from the current price. This is not investment advice.

What is TG Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates TG Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.

TG Therapeutics discussion 0 comments

Add a comment